Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma

Sonali M. Smith, Linda J. Burns, David J. Inwards, Koen Van Besien, Peter H. Wiernik, Mitchell S. Cairo, Jennifer Le Rademacher, Wensheng He, Parameswaran N. Hari, Timothy S. Fenske, Ritsuro Suzuki, Jack W. Hsu, Gregory A. Hale, Dipnarine Maharaj, Harry C. Schouten, Leona A. Holmberg, Anna Sureda, Robert Peter Gale, Silvia Montoto, Cesar O. FreytesRichard Maziarz, Thomas G. Gross, Hillard M. Lazarus, Luciano J. Costa, Ginna G. Laport

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n =115; median age, 43 years) or allogeneic HCT (alloHCT; n= 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes. Results AutoHCT recipients were more likely in first complete remission (CR1; 35% v 14%; P <.001) and with chemotherapy-sensitive disease (86% v 60%; P <.001), anaplastic large-cell histology (53% v 40%; P <.04), and two or fewer lines of prior therapy (65% v 44%; P <.001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42% and 53%, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31% remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95% CI, 1.80 to 6.99; P <.001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95% CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95% CI, 2.15 to 11.72) were prognostic of survival. Conclusion These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.

Original languageEnglish (US)
Pages (from-to)3100-3109
Number of pages10
JournalJournal of Clinical Oncology
Volume31
Issue number25
DOIs
StatePublished - Sep 1 2013

Fingerprint

T-Cell Lymphoma
Cell Transplantation
Non-Hodgkin's Lymphoma
Anaplastic Large-Cell Lymphoma
Disease-Free Survival
Survival
Histology
Peripheral T-Cell Lymphoma
Recurrence
Drug Therapy
Mortality
Proportional Hazards Models
Multivariate Analysis
Transplantation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Smith, S. M., Burns, L. J., Inwards, D. J., Van Besien, K., Wiernik, P. H., Cairo, M. S., ... Laport, G. G. (2013). Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. Journal of Clinical Oncology, 31(25), 3100-3109. https://doi.org/10.1200/JCO.2012.46.0188

Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. / Smith, Sonali M.; Burns, Linda J.; Inwards, David J.; Van Besien, Koen; Wiernik, Peter H.; Cairo, Mitchell S.; Le Rademacher, Jennifer; He, Wensheng; Hari, Parameswaran N.; Fenske, Timothy S.; Suzuki, Ritsuro; Hsu, Jack W.; Hale, Gregory A.; Maharaj, Dipnarine; Schouten, Harry C.; Holmberg, Leona A.; Sureda, Anna; Gale, Robert Peter; Montoto, Silvia; Freytes, Cesar O.; Maziarz, Richard; Gross, Thomas G.; Lazarus, Hillard M.; Costa, Luciano J.; Laport, Ginna G.

In: Journal of Clinical Oncology, Vol. 31, No. 25, 01.09.2013, p. 3100-3109.

Research output: Contribution to journalArticle

Smith, SM, Burns, LJ, Inwards, DJ, Van Besien, K, Wiernik, PH, Cairo, MS, Le Rademacher, J, He, W, Hari, PN, Fenske, TS, Suzuki, R, Hsu, JW, Hale, GA, Maharaj, D, Schouten, HC, Holmberg, LA, Sureda, A, Gale, RP, Montoto, S, Freytes, CO, Maziarz, R, Gross, TG, Lazarus, HM, Costa, LJ & Laport, GG 2013, 'Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma', Journal of Clinical Oncology, vol. 31, no. 25, pp. 3100-3109. https://doi.org/10.1200/JCO.2012.46.0188
Smith SM, Burns LJ, Inwards DJ, Van Besien K, Wiernik PH, Cairo MS et al. Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. Journal of Clinical Oncology. 2013 Sep 1;31(25):3100-3109. https://doi.org/10.1200/JCO.2012.46.0188
Smith, Sonali M. ; Burns, Linda J. ; Inwards, David J. ; Van Besien, Koen ; Wiernik, Peter H. ; Cairo, Mitchell S. ; Le Rademacher, Jennifer ; He, Wensheng ; Hari, Parameswaran N. ; Fenske, Timothy S. ; Suzuki, Ritsuro ; Hsu, Jack W. ; Hale, Gregory A. ; Maharaj, Dipnarine ; Schouten, Harry C. ; Holmberg, Leona A. ; Sureda, Anna ; Gale, Robert Peter ; Montoto, Silvia ; Freytes, Cesar O. ; Maziarz, Richard ; Gross, Thomas G. ; Lazarus, Hillard M. ; Costa, Luciano J. ; Laport, Ginna G. / Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 25. pp. 3100-3109.
@article{2ab1e7630dfb429ba797bf39593c3436,
title = "Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma",
abstract = "Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n =115; median age, 43 years) or allogeneic HCT (alloHCT; n= 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes. Results AutoHCT recipients were more likely in first complete remission (CR1; 35{\%} v 14{\%}; P <.001) and with chemotherapy-sensitive disease (86{\%} v 60{\%}; P <.001), anaplastic large-cell histology (53{\%} v 40{\%}; P <.04), and two or fewer lines of prior therapy (65{\%} v 44{\%}; P <.001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42{\%} and 53{\%}, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31{\%} remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95{\%} CI, 1.80 to 6.99; P <.001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95{\%} CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95{\%} CI, 2.15 to 11.72) were prognostic of survival. Conclusion These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.",
author = "Smith, {Sonali M.} and Burns, {Linda J.} and Inwards, {David J.} and {Van Besien}, Koen and Wiernik, {Peter H.} and Cairo, {Mitchell S.} and {Le Rademacher}, Jennifer and Wensheng He and Hari, {Parameswaran N.} and Fenske, {Timothy S.} and Ritsuro Suzuki and Hsu, {Jack W.} and Hale, {Gregory A.} and Dipnarine Maharaj and Schouten, {Harry C.} and Holmberg, {Leona A.} and Anna Sureda and Gale, {Robert Peter} and Silvia Montoto and Freytes, {Cesar O.} and Richard Maziarz and Gross, {Thomas G.} and Lazarus, {Hillard M.} and Costa, {Luciano J.} and Laport, {Ginna G.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1200/JCO.2012.46.0188",
language = "English (US)",
volume = "31",
pages = "3100--3109",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma

AU - Smith, Sonali M.

AU - Burns, Linda J.

AU - Inwards, David J.

AU - Van Besien, Koen

AU - Wiernik, Peter H.

AU - Cairo, Mitchell S.

AU - Le Rademacher, Jennifer

AU - He, Wensheng

AU - Hari, Parameswaran N.

AU - Fenske, Timothy S.

AU - Suzuki, Ritsuro

AU - Hsu, Jack W.

AU - Hale, Gregory A.

AU - Maharaj, Dipnarine

AU - Schouten, Harry C.

AU - Holmberg, Leona A.

AU - Sureda, Anna

AU - Gale, Robert Peter

AU - Montoto, Silvia

AU - Freytes, Cesar O.

AU - Maziarz, Richard

AU - Gross, Thomas G.

AU - Lazarus, Hillard M.

AU - Costa, Luciano J.

AU - Laport, Ginna G.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n =115; median age, 43 years) or allogeneic HCT (alloHCT; n= 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes. Results AutoHCT recipients were more likely in first complete remission (CR1; 35% v 14%; P <.001) and with chemotherapy-sensitive disease (86% v 60%; P <.001), anaplastic large-cell histology (53% v 40%; P <.04), and two or fewer lines of prior therapy (65% v 44%; P <.001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42% and 53%, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31% remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95% CI, 1.80 to 6.99; P <.001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95% CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95% CI, 2.15 to 11.72) were prognostic of survival. Conclusion These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.

AB - Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n =115; median age, 43 years) or allogeneic HCT (alloHCT; n= 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes. Results AutoHCT recipients were more likely in first complete remission (CR1; 35% v 14%; P <.001) and with chemotherapy-sensitive disease (86% v 60%; P <.001), anaplastic large-cell histology (53% v 40%; P <.04), and two or fewer lines of prior therapy (65% v 44%; P <.001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42% and 53%, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31% remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95% CI, 1.80 to 6.99; P <.001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95% CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95% CI, 2.15 to 11.72) were prognostic of survival. Conclusion These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.

UR - http://www.scopus.com/inward/record.url?scp=84886463678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886463678&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.46.0188

DO - 10.1200/JCO.2012.46.0188

M3 - Article

C2 - 23897963

AN - SCOPUS:84886463678

VL - 31

SP - 3100

EP - 3109

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -